Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis

Main Article Content

Andrew Blauvelt
Craig Leonardi
Claus Zachariae
Russel Burge
Terri Ridenour
Missy McKean-Matthews
Sandra Garces
Gregory Cameron

Keywords

psoriasis, ixekizumab, clinical trial

Abstract

Abstract Not Available